Loading...
•
Sep 30, 2024
Iovance Q3 2024 Earnings Report
Iovance reported Q3 2024 financial results with significant demand for Amtagvi™ and total product revenue of $58.6M.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $83.5 million for Q3 2024, with revenue of $58.6 million driven by Amtagvi and Proleukin sales. The company's cash position as of September 30, 2024, was approximately $403.8 million, expected to fund operations into early 2026.
Total product revenue reached $58.6 million in Q3 2024.
Amtagvi revenue was $42.1 million for completed infusions in Q3 2024.
Proleukin global revenue was $16.5 million in Q3 2024.
Cash position as of September 30, 2024, was approximately $403.8 million, expected to fund operations into early 2026.
Forward Guidance
Iovance reaffirms guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue. Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025.
Positive Outlook
- Reaffirming guidance of $160-$165M for FY24 of Total Product Revenue.
- Reaffirming guidance of $450-$475M for FY25 of Total Product Revenue.
- Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025.
- Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval in EU and Canada in 2H2025.
- Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...